AI-EXPO
6.6.2018 18:27:09 CEST | Business Wire | Press release
Arriving in Amsterdam on the 27-28 June , the second annual AI Expo Europe event will host 2 co-located events covering IoT and Blockchain , with 8,000 attendees expected to attend including CTO’s, CDO’s, Head’s of Innovation and Technology, IT Directors, Developers & Start-Up’s, OEM’s, Government, Automotive, Operators, Technology Providers, Investors, VCs and many more. The AI Expo will showcase the most cutting-edge technologies from more than 300 exhibitors and provide insight from over 300 speakers sharing their unparalleled industry knowledge and real-life experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006061/en/
1. The exhibition and start-up incubator zone
The event will host a dedicated start-up incubator zone where you can see the latest AI & IoT technologies and innovations in action, in addition to the vast exhibition of 300+ companies who will be showcasing their products and services within the field of AI, IoT & Blockchain. Expect to see demos and booths from Microsoft, IBM, PTC, Kore, Hercules, Thales, Rutronik, Enterprise Ethereum Alliance, BPU Holdings, Start-up Amsterdam, ML6, Bottos, Ortec Data Science, Adani, NTR Labs, Prosper BI and many more. Start-ups within the incubator zone include Aiir Innovations, Botsquad, Mercury.AI, IoTify, Porter, 3D Universium, Zazu, 904 Labs, Innovation in Motion, Blockhearts, Mind Trace, Sightcorp, Cupenya, Effect.Ai, Sodaq, Amberscript, BrainCreators, Clockworks to name a few. In addition, attendees can join speakers from Aiir Innovations, Mercury.AI and BrainCreators within the AI Technologies track on day 2 (28th June) as they explore innovative artificial intelligence techniques.
2. 10 Conference Tracks covering AI, IoT and Blockchain
Your Free Expo Pass will provide access to 10 conference tracks; AI Technologies , Data Analytics for AI & IoT, Developing for the IoT , Privacy & Security , IoT Innovations & Technologies , ICOs & Token Investments, Blockchain for Business , Developing Blockchain Applications , Blockchain Technologies and Blockchain Strategies. Register for your free expo pass here.
3. Keynote Panel: IoT and AI data analytics for intelligent decision making
Taking place on the 27th June at 10.15am within the Data Analytics for AI & IoT conference track, the Chief Data Scientist at Southern Water , a Data Scientist from Monsanto, a Data Scientist from Marel Poulty and the CEO from the predictive intelligence firm Prosper BI will be identifying target-rich, high-value data that can be used to generate business intelligence, looking at the use of cloud analytics platforms to derive value from AI & IoT data, and discussing the barriers to widespread AI/IoT/Big Data value delivery and how these might be overcome.
4. Machine Learning and AI: Do’s and Don’ts in the online food provider industry
Adrian Foltyn, Former Head/Director of Data Science at HelloFresh, the online food survival kit provider, will take to the stage within the Data & Analytics for AI & IoT track on the 27 June at 15.20pm. Adrian will discuss why preference data is at the core of the company’s operations as their predictive technologies forecast the food that their consumers want during certain seasons.
5. AI and Computer Vision – Intelligent Assistants and an extra pair of eyes…
Join Miriam Huijser, Co-Founder & Chief Research Officer at Aiir Innovations on 28 June within the AI Technologies conference track as she explores how intelligence assistants can be used to inspect aircraft engines using state-of-the-art computer vision techniques. Aiir Innovations is an Amsterdam based start-up that aims to bring artificial intelligence to the maintenance and aircraft industry. They will also be exhibiting within the start-up incubator zone within the expo floor.
6. 2 co-located events
Co-located with the IoT Tech Expo and the Blockchain Expo, the AI Exhibition and Conference will allow you to explore 3 ecosystems in 1 and discover how the convergence of these 3 areas is powering the future of technology!
7. Using Big Data to create intelligent data models
Within the dedicated Data Analytics for AI & IoT track on the 27 June at 14.40pm, join AI & IoT thought leaders as they take to the stage for a panel discussion. Hear from Christophe Eschenbrenner, IoT & Data Foundations Program Manager from Alstom Digital Mobility , Violeta Misheva, Data Scientist at ABN AMRO Bank N.V. , Filippo F.G. Della Casa, Head of Analytics at Unipol and Dor Kedem, Senior Data Scientist at ING as they discuss the increased need for big data analytics to drive AI & Machine Learning across a range of industries.
Other event features include exclusive networking opportunities
Following the first day of the event, Speakers, Sponsors, Press, Ultimate, Gold and Expo Plus attendees are invited to attend an evening of networking.
The Beach House will host the official networking party. It is located at the entrance of The Beach and surrounded by stunning beach scenery. Set away from the busier main structures and with its own bar and terrace. Discuss the topics from the conferences and build relationships with like-minded companies and individuals.
To register for your networking (Ultimate/ Gold/ Expo Plus) pass, click here.
The final advance rate ends 15 June so if you are looking for full conference and networking access, you can save up to €150 on your conference and networking pass (Gold/Ultimate) when you book by then.
You can find out more about the World Series 2018 and register for each event here:
AI Expo Europe – 27-28 th June 2018, RAI, Amsterdam
AI Expo North America – 28-29 th November 2018, Santa Clara, Silicon Valley
AI Expo Global – 25-26 th April 2019 , Olympia Grand, London
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606006061/en/
Contact:
Anna Fry
Marketing Executive | AI Expo
anna@ai-expo.net
www.ai-expo.net/
+44
(0) 117 980 9020
Link:
Social Media:
https://www.facebook.com/aiexpoworldseries/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom